​

60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)

RevenueFinancialsChart

Previous Close

$3.95

52W Range

$1.36 - $17.68

50D Avg

$3.30

200D Avg

$6.03

Market Cap

$3.19M

Avg Vol (3M)

$3.52M

Beta

2.96

Div Yield

-

SXTP Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Jul 12, 2023

Website

SXTP Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceSep 24Jun 24Mar 24
Service$10.79K$10.79K$10.79K
Product$135.29K$124.97K-

Fiscal year ends in Dec 24 | Currency in USD

SXTP Financial Summary

Dec 24Dec 23Dec 22
Revenue$607.57K$253.57K$223.21K
Operating Income$-9.71M$-5.15M$-1.75M
Net Income$-7.96M$-3.77M$-6.18M
EBITDA$-9.71M$-1.43M$-2.11M
Basic EPS$-17.50$-0.95$-1.07
Diluted EPS$-17.50$-0.95$-1.07

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
GRIGRI Bio, Inc.
BDRXBiodexa Pharmaceuticals Plc
JAGXJaguar Health, Inc.
KZIAKazia Therapeutics Limited
SNGXSoligenix, Inc.
SILOSilo Pharma, Inc.
CNSPCNS Pharmaceuticals, Inc.
CMNDClearmind Medicine Inc.